CRE Continues its Review of Initiation/Cessation Studies Identified by FDA

As CRE has stated repeatedly in its statements before the TPSAC, the hard science, toxicological studies dealing with acute and chronic effects of menthol,   suggests that such studies are not an area of concern.

Two issues will determine an objective evaluation of the menthol issue, “soft” science dealing with initiation/cessation and contraband considerations.

 CRE has reviewed more that fifty percent of the studies identified by FDA and conclude that either in total, or in part, they are not compliant with the Data Quality Act and therefore can not be used by the FDA.

CRE has reviewed another study described at

Leave a Reply

Please Answer: *